In our study we observed in HCV patients treated with Peg-IFN-α and RBV alone an increase of somatic symptoms, anxiety, depression, insomnia, mood dysfunction, social dysfunction, anger, fatigue, confusion, sleep apnea and poor sleep quality. The gene discussed is IFNA17; the disease is sleep apnea syndrome.